Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT03386513
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
- NCT03386513 ↗
- Active, not recruiting
- AbbVie
- Focused
We haven't built an HCP commentary report on NCT03386513 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03386513 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm
- Interventions
- IMGN632
- Arms
- Escalation and Expansion · Experimental
- Enrollment
- 179
- Primary outcomes
- Composite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Participants
- Sponsor
- AbbVie
- Start
- Jan 2, 2018
- Primary completion
- Oct 2, 2024
- Results posted
- Yes
- Registry record
- NCT03386513 · updated Sep 4, 2026
Publications
linked from the registry- Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ, Erba HP, Wang ES, Walter RB, Deconinck E, Aribi A, Legrand O, Lebon D, Maisano V, Martinelli G, DeAngelo DJ, Derenzini E, Du Y, Lakshmikanthan S, Potluri J, Kantarjian HM, Daver NG. Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2026 Apr;44(10):861-873. doi: 10.1200/JCO-25-02083. Epub 2026 Feb 11. PubMed 41671533
- Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, Sweet KL, Pemmaraju N, Lane AA, Torres-Minana L, Thompson JE, Konopleva MY, Sloss CM, Watkins K, Bedse G, Du Y, Malcolm KE, Zweidler-McKay PA, Kantarjian HM. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol. 2024 Mar;25(3):388-399. doi: 10.1016/S1470-2045(23)00674-5. PubMed 38423051